生物制剂对哮喘合并COVID-19患者可能有益
本文为对Wark等人来信的回复,基于作者既往发表的数据(奥马珠单抗n=641、美泊利单抗n=308、贝那利珠单抗n=98、瑞利珠单抗n=26)及他人观察,作者不同意Th2靶向生物制剂因增加ACE2表达而可能增加哮喘患者SARS-CoV-2易感性的说法,认为生物制剂对哮喘合并COVID-19患者可能有益。
要点
- 作者不同意Th2靶向生物制剂增加哮喘患者SARS-CoV-2易感性的观点。
- 既往数据中生物制剂(奥马珠单抗n=641等)提示对哮喘合并COVID-19患者有益。
- 需进一步探索呼吸疾病与SARS-CoV-2感染的关系及机制。
核心结论
- 基于他人及自身观察,作者认为Th2靶向生物制剂对哮喘合并COVID-19患者可能有益,而非增加SARS-CoV-2易感性。
研究设计与样本
- 本文为对P.A.B. Wark等人来信的回复,引用作者既往发表论文表3中生物制剂使用数据(奥马珠单抗n=641、美泊利单抗n=308、贝那利珠单抗n=98、瑞利珠单抗n=26)。
主要发现
- 作者既往论文表3中生物制剂数据(奥马珠单抗n=641、美泊利单抗n=308、贝那利珠单抗n=98、瑞利珠单抗n=26)提示对哮喘合并COVID-19患者有益。
- 作者不同意生物制剂因增加ACE2表达而增加SARS-CoV-2易感性的说法。
临床怎么用
- 对哮喘患者使用Th2靶向生物制剂时,不应基于ACE2表达增加的推测而顾虑其增加SARS-CoV-2易感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biologics may have a beneficial effect in asthma patients with COVID-19 https://bit.ly/3hkor8X We take the opportunity to respond to P.A.B. Wark and co-workers, and their correspondence on the subject of our recent publication [1]. It is indeed worth exploring the relationships of respiratory disease and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential mechanisms involved to understand better the pathophysiology of coronavirus disease 2019 (COVID-19), and eventually consider new treatments. However, based on others and our own observations, we disagree with the statement that use of Th2 targeting biologics in patients with asthma may increase susceptibility to SARS-CoV-2 infection due to an increased expression of ACE2. The results in table 3 of our manuscript [1] with biologics (omalizumab n=641, mepolizumab n=308, benralizumab n=98, reslizumab n=26) point to a beneficial effect in asthmatics with COVID-19, as suggested elsewhere [2].
引用
- Izquierdo JL, Soriano JB. Biologics may have a beneficial effect in asthma patients with COVID-19. Eur Respir J. 2021. PMID: 34244322. doi:10.1183/13993003.01076-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。